Pyridopyrimidinone inhibitors of PIM-1 and/or PIM-3
Compounds of formula (I), useful for inhibiting PIM-I and/or PIM-3: and pharmaceutically acceptable salts thereof, wherein Y, Z, R 1 , R 3 , Q, X and R 4 are as defined above. Pharmaceutical compositions and methods of treating diseases and conditions, such as cancer, are also disclosed.
1. A compound according to formula I
or pharmaceutically acceptable salts thereof, wherein
Q is tetrazolyl;
X is —C(O)—;
R 1 is a halogen;
R 2 and R 5 are independently H or halogen;
R 3 is H, chloro, bromo, methyl, NR 6 R 7 , or methoxy;
R 4 is C 1 -C 7 alkyl, which is optionally substituted with C 2 -C 4 alkenyl, C 1 -C 4 alkoxy, NR 6 R 7 , —C 0 -C 6 alkylC(O)OR 6 , —O-phenyl where the phenyl is optionally substituted with 1, 2, or 3 groups that are independently, halogen, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, hydroxyl, 4-methylpiperazin-1-yl, CF 3 , or OCF 3 .
R 6 and R 7 at each occurrence are independently H, C 1 -C 4 alkyl, C 2 -C 4 alkanoyl, or phenylC 1 -C 4 alkyl;
Y is CR 5 ; and
Z is CR 2 .
2. A compound according to formula I
or pharmaceutically acceptable salts thereof, wherein
Q is tetrazolyl;
X is —C(O)—;
R 1 is a halogen;
R 2 and R 5 are independently H or halogen;
R 3 is H, chloro, bromo, methyl, NR 6 R 7 , or methoxy;
R 4 is heteroaryl or heteroaryl C 1 -C 6 alkyl, each of which is optionally substituted with one or more groups, where each group is independently C 1 -C 6 alkyl, C 1 -C 6 alkoxy, halogen, —SO 2 —(C 1 -C 4 alkyl), —S—(C 1 -C 4 alkyl), C 1 -C 6 haloalkyl, C 1 -C 6 haloalkoxy, C 1 -C 6 alkoxy C 1 -C 6 alkyl, NR 6 R 7 , C 2 -C 6 alkanoyl, aryl, or C 1 -C 6 alkyl substituted with C 1 -C 6 alkoxycarbonyl, where the aryl is selected from phenyl and naphthyl, and where the aryl is optionally substituted with one or more groups, where each group is independently halogen, C 1 -C 6 haloalkyl, C 1 -C 6 haloalkoxy, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, or hydroxy;
R 6 and R 7 at each occurrence are independently H, C 1 -C 4 alkyl, C 2 -C 4 alkanoyl, or phenylC 1 -C 4 alkyl;
Y is CR 5 ; and
Z is CR 2 .
3. A compound according to claim 2 , wherein
R 4 is heteroaryl or heteroaryl C 1 -C 6 alkyl, where the heteroaryl group is thienyl, thiadiazolyl, oxazolyl, benzothienyl, isoxazolyl, benzofuranyl, pyridyl, pyrazolyl, or furanyl, each of which is optionally substituted with one or more groups, where each group is independently halogen, C 1 -C 4 alkyl, —SO 2 —(C 1 -C 4 alkyl), —S—(C 1 -C 4 alkyl), C 1 -C 4 alkoxy, or aryl, where the aryl is phenyl optionally substituted with one or more groups, where each group is independently halogen, C 1 -C 4 haloalkyl, C 1 -C 4 haloalkoxy, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, or hydroxy.
4. A compound according formula I
or pharmaceutically acceptable salts thereof, wherein
Q is tetrazolyl;
X is —C(O)—;
R 1 is a halogen;
R 2 and R 5 are independently H or halogen;
R 3 is H, chloro, bromo, methyl, NR 6 R 7 , or methoxy;
R 4 is heterocycloalkyl or heterocycloalkyl C 1 -C 6 alkyl, each of which is optionally substituted with one or more groups, where each group is independently C 1 -C 6 alkyl, C 1 -C 6 alkoxy, halogen, C 1 -C 6 haloalkyl, C 1 -C 6 haloalkoxy, C 1 -C 6 alkoxy C 1 -C 6 alkyl, NR 6 R 7 , C 2 -C 6 alkanoyl, aryl, or C 1 -C 6 alkyl substituted with C 1 -C 6 alkoxycarbonyl, where the aryl is selected from phenyl and naphthyl, and where the aryl is optionally substituted with one or more groups, where each group is that are independently halogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, or hydroxy;
R 6 and R 7 at each occurrence are independently H, C 1 -C 4 alkyl, C 2 -C 4 alkanoyl, or phenylC 1 -C 4 alkyl;
Y is CR 5 ; and
Z is CR 2 .
5. A compound according to claim 4 , wherein
R 4 is heterocycloalkyl or heterocycloalkyl C 1 -C 6 alkyl, where the heterocycloalkyl group is 3-oxo-2-oxabicyclo[2.2.1]heptanyl, piperidinyl, or tetrahydrofuranyl, each of which is optionally substituted with one or more groups, where each group is independently C 1 -C 6 alkyl, C 1 -C 6 alkoxy, halogen, C 1 -C 4 haloalkyl, C 1 -C 4 haloalkoxy, C 1 -C 6 alkoxy C 1 -C 6 alkyl, NR 6 R 7 , C 2 -C 6 alkanoyl, aryl, or C 1 -C 6 alkyl substituted with C 1 -C 6 alkoxycarbonyl, the aryl is selected from phenyl and naphthyl, where the aryl is optionally substituted with one or more groups, where each group is independently halogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, or hydroxy.
6. A compound according to claim 5 , wherein
R 4 is heterocycloalkyl or heterocycloalkyl C 1 -C 6 alkyl, where the heterocycloalkyl group is 3-oxo-2-oxabicyclo[2.2.1]heptane substituted with one or more methyl groups, piperidinyl substituted with C 2 -C 4 alkanoyl, or tetrahydrofuranyl.
7. A compound selected from one of:
3-Chloro-N-(5-chloro-2-(1H-tetrazol-5-yl)phenyl)thiophene-2-carboxamide;
N-[5-Chloro-2-(1H-tetrazol-5-yl)phenyl]-2,2-dimethylpropanamide;
N-[5-Chloro-2-(1H-tetrazol-5-yl)phenyl]cyclohexanecarboxamide;
N-[5-Chloro-2-(1H-tetrazol-5-yl)phenyl]-2-methylpropanamide;
N-[5-Chloro-2-(1H-tetrazol-5-yl)phenyl]-2-methylbutanamide;
N-[5-Chloro-2-(1H-tetrazol-5-yl)phenyl]-4-methyl-1,2,3-thiadiazole-5-carboxamide;
N-[5-Chloro-2-(1H-tetrazol-5-yl)phenyl]-2-cyclopentylacetamide;
(4R)—N-[5-Chloro-2-(1H-tetrazol-5-yl)phenyl]-4,7,7-trimethyl-3-oxo-2-oxabicyclo[2.2.1]heptane-1-carboxamide;
N-[5-Chloro-2-(1H-tetrazol-5-yl)phenyl]-3-methylbutanamide;
N-[5-Chloro-2-(1H-tetrazol-5-yl)phenyl]-5-methylisoxazole-3-carboxamide;
N-[5-Chloro-2-(1H-tetrazol-5-yl)phenyl]-2-(2-thienyl)acetamide;
N-[5-Chloro-2-(1H-tetrazol-5-yl)phenyl]-2-methylpentanamide;
3-Chloro-N-[5-chloro-2-(1H-tetrazol-5-yl)phenyl]-1-benzothiophene-2-carboxamide;
N-[5-Chloro-2-(1H-tetrazol-5-yl)phenyl]pentanamide;
N-[5-Chloro-2-(1H-tetrazol-5-yl)phenyl]isoxazole-5-carboxamide;
(3s,5s,7s)-N-[5-Chloro-2-(1H-tetrazol-5-yl)phenyl]tricyclo[3.3.1.1˜3,7˜]decane-1-carboxamide;
N-[5-Chloro-2-(1H-tetrazol-5-yl)phenyl]-2-ethylbutanamide;
N-[5-Chloro-2-(1H-tetrazol-5-yl)phenyl]butanamide;
N-[5-Chloro-2-(1H-tetrazol-5-yl)phenyl]cyclopentanecarboxamide;
N-[5-Chloro-2-(1H-tetrazol-5-yl)phenyl]-3,5-dimethylisoxazole-4-carboxamide;
N-[5-Chloro-2-(1H-tetrazol-5-yl)phenyl]propanamide;
N-[5-Chloro-2-(1H-tetrazol-5-yl)phenyl]-1-benzothiophene-2-carboxamide;
N-[5-Chloro-2-(1H-tetrazol-5-yl)phenyl]-4-methylpentanamide;
N-[5-Chloro-2-(1H-tetrazol-5-yl)phenyl]-2-(methyloxy)acetamide;
N-[5-Chloro-2-(1H-tetrazol-5-yl)phenyl]-N˜2˜,N˜2˜-dimethylglycinamide;
Ethyl 3-{[5-chloro-2-(1H-tetrazol-5-yl)phenyl]amino}-3-oxopropanoate;
N-[5-Chloro-2-(1H-tetrazol-5-yl)phenyl]-5-methyl-3-phenylisoxazole-4-carboxamide;
N-[3-Chloro-2-(1H-tetrazol-5-yl)phenyl]thiophene-2-carboxamide;
N-[2-Chloro-6-(1H-tetrazol-5-yl)phenyl]thiophene-2-carboxamide;
N-[5-Chloro-2-(1H-tetrazol-5-yl)phenyl]-3-methyl-1-benzofuran-2-carboxamide;
N-{2-[(Phenylmethyl)amino]-5-(1H-tetrazol-5-yl)pyrimidin-4-yl}thiophene-2-carboxamide;
N-[6-(1H-Tetrazol-5-yl)-1H-benzimidazol-5-yl]thiophene-2-carboxamide;
N-[5-Chloro-2-(1H-tetrazol-5-yl)phenyl]-2-ethylhexanamide;
N-[5-Chloro-2-(1H-tetrazol-5-yl)phenyl]-2-(phenyloxy)acetamide;
Methyl 4-{[5-chloro-2-(1H-tetrazol-5-yl)phenyl]amino}-4-oxobutanoate;
(1R,2R)—N-[5-Chloro-2-(1H-tetrazol-5-yl)phenyl]-2-phenylcyclopropanecarboxamide;
3-(2-Chlorophenyl)-N-[5-chloro-2-(1H-tetrazol-5-yl)phenyl]-5-methylisoxazole-4-carboxamide;
2-Chloro-N-[5-chloro-2-(1H-tetrazol-5-yl)phenyl]pyridine-3-carboxamide;
N-[5-Chloro-2-(1H-tetrazol-5-yl)phenyl]-2-(methylthio)pyridine-3-carboxamide;
3-(2-Chloro-6-fluorophenyl)-N-[5-chloro-2-(1H-tetrazol-5-yl)phenyl]-5-methylisoxazole-4-carboxamide;
3-Chloro-N-[5-chloro-2-(1H-tetrazol-5-yl)phenyl]-4-(methylsulfonyl)thiophene-2-carboxamide;
N-[5-Chloro-2-(1H-tetrazol-5-yl)phenyl]-2,5-dimethylfuran-3-carboxamide;
N-[5-Chloro-2-(1H-tetrazol-5-yl)phenyl]pent-4-enamide;
N-[5-Chloro-2-(1H-tetrazol-5-yl)phenyl]cyclopropanecarboxamide;
5-Chloro-N-[5-chloro-2-(1H-tetrazol-5-yl)phenyl]-1-methyl-1H-pyrazole-4-carboxamide;
2-[(4-Chlorophenyl)oxy]-N-[5-chloro-2-(1H-tetrazol-5-yl)phenyl]acetamide;
2-[(3-Chlorophenyl)oxy]-N-[5-chloro-2-(1H-tetrazol-5-yl)phenyl]acetamide;
N-[5-Chloro-2-(1H-tetrazol-5-yl)phenyl]-2-{[3-(methyloxy)phenyl]oxy}acetamide;
N-[5-Chloro-2-(1H-tetrazol-5-yl)phenyl]-3-(phenyloxy)propanamide;
N-[5-Chloro-2-(1H-tetrazol-5-yl)phenyl]-3-[(4-fluorophenyl)oxy]propanamide;
N-[5-Chloro-2-(1H-tetrazol-5-yl)phenyl]cyclobutanecarboxamide; and
N-[5-Chloro-2-(1H-tetrazol-5-yl)phenyl]-2-{[2-(4-methylpiperazin-1-yl)phenyl]oxy}acetamide;
or a pharmaceutically acceptable salt thereof.
8. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, excipient or solvent.
9. A pharmaceutical composition comprising a compound of claim 2 , or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, excipient or solvent.
10. A pharmaceutical composition comprising a compound of claim 4 , or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, excipient or solvent.